Noriyuki Ouchi Selected Research

Adiponectin

07/2008	A novel role for adiponectin in the regulation of inflammation.
07/2008	Circulating adiponectin levels in patients with atrial fibrillation.
06/2008	Usefulness of adiponectin to predict myocardial salvage following successful reperfusion in patients with acute myocardial infarction.
01/2008	Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease.
06/2007	Adiponectin protects against the development of systolic dysfunction following myocardial infarction.
06/2007	Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment.
06/2006	Adiponectin replenishment ameliorates obesity-related hypertension.
10/2005	Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms.
09/2005	Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism.
07/2004	Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling.
04/2004	Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease.
12/2003	Obesity, adiponectin and vascular inflammatory disease.
06/2003	Disturbed secretion of mutant adiponectin associated with the metabolic syndrome.
05/2003	Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors.
11/2002	Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice.
10/2002	Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis.
09/2002	Adiponectin in essential hypertension.
07/2002	Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.
07/2002	Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome.
01/2002	Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.

Articles by Research Topic

Disease

3	Syndrome 04/2004 - 07/2002
2	Myocardial Infarction 06/2008 - 06/2007
2	Coronary Artery Disease (Coronary Atherosclerosis) 01/2008 - 04/2004
2	Reperfusion Injury 06/2007 - 10/2005
2	Hypertension (High Blood Pressure) 06/2006 - 09/2002
2	Obesity 06/2006 - 12/2003
2	Insulin Resistance 07/2002 - 07/2002
1	Inflammation 07/2008
1	Atrial Fibrillation 07/2008
1	Myocardial Ischemia (Ischemic Heart Diseases) 10/2005
1	Heart Failure 09/2005
1	Ischemia 07/2004
1	Nephrotic Syndrome (Syndrome, Nephrotic) 05/2003
1	Atherosclerosis (Atheroma) 11/2002
1	Pathologic Constriction (Stenosis) 10/2002
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2002

Drug/Important Bio-Agent (IBA)

20	AdiponectinIBA 07/2008 - 01/2002
1	Glucose (Dextrose)FDA LinkGeneric 09/2005
1	ApolipoproteinsIBA 11/2002